Chronic Airway Disease and Multimorbidity Cohort
CAM Cohort
1 other identifier
observational
2,000
1 country
9
Brief Summary
Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated. Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization. Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2025
Typical duration for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 2, 2025
CompletedFirst Posted
Study publicly available on registry
January 29, 2025
CompletedStudy Start
First participant enrolled
February 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2028
February 17, 2025
February 1, 2025
3.5 years
January 2, 2025
February 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Length of hospital stay
The length of time participants remain hospitalized from the date of admission to the date of discharge or death, whichever comes first.
From the date of admission until discharge or death, assessed over an estimated period of 3 to 30 days.
Secondary Outcomes (9)
Acute exacerbation during follow-up
From the date of discharge to 12 months post-discharge.
All cause mortality
In-hospital and from enrollment to 12 months.
Quality of Life in COPD Patients
From enrollment to 12 months.
Quality of Life in Asthma Patients
From enrollment to 12 months
Quality of Life in Bronchiectasis Patients
From enrollment to 12 months.
- +4 more secondary outcomes
Study Arms (3)
COPD group
Asthma Group
Bronchiectasis Group
Eligibility Criteria
The CAM cohort study focuses on hospitalized patients with chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis, during acute exacerbation episodes. Participants are recruited from 9 medical centers across China, representing diverse geographic and clinical settings.
You may qualify if:
- Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age;
- The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis".
You may not qualify if:
- Patients were unable to undergo spirometry during the stabilization period;
- Expected survival is less than 1 month;
- Refusal to sign an informed consent form;
- Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion;
- Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- China-Japan Friendship Hospitallead
- Second Affiliated Hospital of Xi'an Jiaotong Universitycollaborator
- First Hospital of China Medical Universitycollaborator
- Henan Provincial People's Hospitalcollaborator
- Second Xiangya Hospital of Central South Universitycollaborator
- Sichuan Universitycollaborator
- Southern Medical University, Chinacollaborator
- Ruijin Hospitalcollaborator
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technologycollaborator
Study Sites (9)
National Center for Respiratory Medicine, China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110001, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710114, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, 200025, China
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Biospecimen
blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ting Yang, MD
China-Japan Friendship Hospital, National Center for Respiratory Medicine
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 2, 2025
First Posted
January 29, 2025
Study Start
February 1, 2025
Primary Completion (Estimated)
July 31, 2028
Study Completion (Estimated)
July 31, 2028
Last Updated
February 17, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share
The CAM cohort study has determined that individual participant data (IPD) will not be directly shared. Instead, supporting information and aggregated results will be made available in specific formats to ensure transparency while protecting participant privacy.